162 related articles for article (PubMed ID: 15165835)
1. Rasagiline enhances L-DOPA-induced contralateral turning in the unilateral 6-hydroxydopamine-lesioned guinea-pig.
Moses D; Gross A; Finberg JP
Neuropharmacology; 2004 Jul; 47(1):72-80. PubMed ID: 15165835
[TBL] [Abstract][Full Text] [Related]
2. Neuroprotective effect of rasagiline in a rodent model of Parkinson's disease.
Blandini F; Armentero MT; Fancellu R; Blaugrund E; Nappi G
Exp Neurol; 2004 Jun; 187(2):455-9. PubMed ID: 15144871
[TBL] [Abstract][Full Text] [Related]
3. Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease.
Guay DR
Am J Geriatr Pharmacother; 2006 Dec; 4(4):330-46. PubMed ID: 17296539
[TBL] [Abstract][Full Text] [Related]
4. Motor stimulant effects of the adenosine A2A receptor antagonist SCH 58261 do not develop tolerance after repeated treatments in 6-hydroxydopamine-lesioned rats.
Pinna A; Fenu S; Morelli M
Synapse; 2001 Mar; 39(3):233-8. PubMed ID: 11284438
[TBL] [Abstract][Full Text] [Related]
5. Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline.
Kupsch A; Sautter J; Götz ME; Breithaupt W; Schwarz J; Youdim MB; Riederer P; Gerlach M; Oertel WH
J Neural Transm (Vienna); 2001; 108(8-9):985-1009. PubMed ID: 11716151
[TBL] [Abstract][Full Text] [Related]
6. Selective inhibition of monoamine oxidase A or B reduces striatal oxidative stress in rats with partial depletion of the nigro-striatal dopaminergic pathway.
Aluf Y; Vaya J; Khatib S; Loboda Y; Finberg JP
Neuropharmacology; 2013 Feb; 65():48-57. PubMed ID: 22982254
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
Chen JJ; Swope DM; Dashtipour K
Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
[TBL] [Abstract][Full Text] [Related]
8. The novel type B MAO inhibitor PF9601N enhances the duration of L-DOPA-induced contralateral turning in 6-hydroxydopamine lesioned rats.
Prat G; Pérez V; Rubi A; Casas M; Unzeta M
J Neural Transm (Vienna); 2000; 107(4):409-17. PubMed ID: 11215752
[TBL] [Abstract][Full Text] [Related]
9. CSC, an adenosine A(2A) receptor antagonist and MAO B inhibitor, reverses behavior, monoamine neurotransmission, and amino acid alterations in the 6-OHDA-lesioned rats.
Aguiar LM; Macêdo DS; Vasconcelos SM; Oliveira AA; de Sousa FC; Viana GS
Brain Res; 2008 Jan; 1191():192-9. PubMed ID: 18164694
[TBL] [Abstract][Full Text] [Related]
10. Intranasally applied L-DOPA alleviates parkinsonian symptoms in rats with unilateral nigro-striatal 6-OHDA lesions.
Chao OY; Mattern C; Silva AM; Wessler J; Ruocco LA; Nikolaus S; Huston JP; Pum ME
Brain Res Bull; 2012 Feb; 87(2-3):340-5. PubMed ID: 22108632
[TBL] [Abstract][Full Text] [Related]
11. Influence of selective inhibition of monoamine oxidase A or B on striatal metabolism of L-DOPA in hemiparkinsonian rats.
Finberg JP; Wang J; Goldstein DS; Kopin IJ; Bankiewicz KS
J Neurochem; 1995 Sep; 65(3):1213-20. PubMed ID: 7643100
[TBL] [Abstract][Full Text] [Related]
12. Rasagiline is neuroprotective in a transgenic model of multiple system atrophy.
Stefanova N; Poewe W; Wenning GK
Exp Neurol; 2008 Apr; 210(2):421-7. PubMed ID: 18222424
[TBL] [Abstract][Full Text] [Related]
13. Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases.
Youdim MB; Fridkin M; Zheng H
Mech Ageing Dev; 2005 Feb; 126(2):317-26. PubMed ID: 15621213
[TBL] [Abstract][Full Text] [Related]
14. Activation of tyrosine kinase receptor signaling pathway by rasagiline facilitates neurorescue and restoration of nigrostriatal dopamine neurons in post-MPTP-induced parkinsonism.
Sagi Y; Mandel S; Amit T; Youdim MB
Neurobiol Dis; 2007 Jan; 25(1):35-44. PubMed ID: 17055733
[TBL] [Abstract][Full Text] [Related]
15. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion.
Gal S; Zheng H; Fridkin M; Youdim MB
J Neurochem; 2005 Oct; 95(1):79-88. PubMed ID: 16181414
[TBL] [Abstract][Full Text] [Related]
16. Increased L-DOPA-derived dopamine following selective MAO-A or -B inhibition in rat striatum depleted of dopaminergic and serotonergic innervation.
Sader-Mazbar O; Loboda Y; Rabey MJ; Finberg JP
Br J Pharmacol; 2013 Nov; 170(5):999-1013. PubMed ID: 23992249
[TBL] [Abstract][Full Text] [Related]
17. Locomotor effects of imidazoline I2-site-specific ligands and monoamine oxidase inhibitors in rats with a unilateral 6-hydroxydopamine lesion of the nigrostriatal pathway.
Macinnes N; Duty S
Br J Pharmacol; 2004 Dec; 143(8):952-9. PubMed ID: 15545290
[TBL] [Abstract][Full Text] [Related]
18. Repeated administration of the monoamine reuptake inhibitor BTS 74 398 induces ipsilateral circling in the 6-hydroxydopamine lesioned rat without sensitizing motor behaviours.
Lane EL; Cheetham SC; Jenner P
Eur J Neurosci; 2005 Jan; 21(1):179-86. PubMed ID: 15654855
[TBL] [Abstract][Full Text] [Related]
19. Increased slow oscillatory activity in substantia nigra pars reticulata triggers abnormal involuntary movements in the 6-OHDA-lesioned rat in the presence of excessive extracellular striatal dopamine.
Meissner W; Ravenscroft P; Reese R; Harnack D; Morgenstern R; Kupsch A; Klitgaard H; Bioulac B; Gross CE; Bezard E; Boraud T
Neurobiol Dis; 2006 Jun; 22(3):586-98. PubMed ID: 16531050
[TBL] [Abstract][Full Text] [Related]
20. "Priming" to dopamine agonist-induced contralateral turning as a model of non-associative sensitization to the expression of the post-synaptic dopamine message.
Morelli M; Fenu S; Pinna A; Cozzolino A; Carta A; Di Chiara G
Behav Pharmacol; 1993; 4(4):389-397. PubMed ID: 11224207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
